221 related articles for article (PubMed ID: 28743407)
21. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
22. MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement.
Hindman N; Kang S; Fournier L; Lakhman Y; Nougaret S; Reinhold C; Sadowski E; Huang JQ; Ascher S
Radiology; 2023 Feb; 306(2):e211658. PubMed ID: 36194109
[TBL] [Abstract][Full Text] [Related]
23. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
24. Laparoscopic versus abdominal myomectomy: practice patterns and health care use in British Columbia.
Chen I; Lisonkova S; Joseph KS; Williams C; Yong P; Allaire C
J Obstet Gynaecol Can; 2014 Sep; 36(9):817-821. PubMed ID: 25222361
[TBL] [Abstract][Full Text] [Related]
25. Incidence of unexpected leiomyosarcoma in a Turkish province: a retrospective multi-centre study in a low income setting.
Taşdemir Ü; Ceran MU; Önder Dirican A; Akar S; Çelik Ç; Energin H; Görkemli H; Mammadova N; Çolak E; Ayhan A
J Obstet Gynaecol; 2022 Aug; 42(6):2208-2212. PubMed ID: 35253591
[TBL] [Abstract][Full Text] [Related]
26. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.
Leibsohn S; d'Ablaing G; Mishell DR; Schlaerth JB
Am J Obstet Gynecol; 1990 Apr; 162(4):968-74; discussion 974-6. PubMed ID: 2327466
[TBL] [Abstract][Full Text] [Related]
27. Uterine leiomyosarcoma: does the primary surgical procedure matter?
Perri T; Korach J; Sadetzki S; Oberman B; Fridman E; Ben-Baruch G
Int J Gynecol Cancer; 2009 Feb; 19(2):257-60. PubMed ID: 19396005
[TBL] [Abstract][Full Text] [Related]
28. Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications.
Desai VB; Wright JD; Schwartz PE; Jorgensen EM; Fan L; Litkouhi B; Lin H; Gross CP; Xu X
Obstet Gynecol; 2018 Apr; 131(4):642-651. PubMed ID: 29528920
[TBL] [Abstract][Full Text] [Related]
29. Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter?
DiNapoli MN; Truong MD; Halfon JK; Burke WM
J Minim Invasive Gynecol; 2018; 25(3):491-497. PubMed ID: 29061369
[TBL] [Abstract][Full Text] [Related]
30. Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.
Xu X; Lin H; Wright JD; Gross CP; Boscoe FP; Hutchison LM; Schwartz PE; Desai VB
J Clin Oncol; 2019 Dec; 37(35):3412-3424. PubMed ID: 31518176
[TBL] [Abstract][Full Text] [Related]
31. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
32. Change in Surgical Practice for Women With Leiomyomas After the U.S. Food and Drug Administration Morcellator Safety Communication.
Clark NM; Schembri M; Jacoby VL
Obstet Gynecol; 2017 Nov; 130(5):1057-1063. PubMed ID: 29016511
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of unexpected leiomyosarcoma at myomectomy: a descriptive study.
Vercellini P; Cribiù FM; Bosari S; Scarfone G; Bolis G; Aimi G; Fedele L
Am J Obstet Gynecol; 2016 Feb; 214(2):292-294. PubMed ID: 26450408
[No Abstract] [Full Text] [Related]
34. Surgical treatment: Myomectomy and hysterectomy; Endoscopy: A major advancement.
Thubert T; Foulot H; Vinchant M; Santulli P; Marzouk P; Borghese B; Chapron C
Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():104-21. PubMed ID: 27400649
[TBL] [Abstract][Full Text] [Related]
35. U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Parker WH; Kaunitz AM; Pritts EA; Olive DL; Chalas E; Clarke-Pearson DL; Berek JS;
Obstet Gynecol; 2016 Jan; 127(1):18-22. PubMed ID: 26646134
[TBL] [Abstract][Full Text] [Related]
36. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.
Desai VB; Wright JD; Gross CP; Lin H; Boscoe FP; Hutchison LM; Schwartz PE; Xu X
Am J Obstet Gynecol; 2019 Jul; 221(1):39.e1-39.e14. PubMed ID: 30853364
[TBL] [Abstract][Full Text] [Related]
37. Risk of unexpected uterine leiomyosarcoma during laparoscopic procedures: Experience from a single tertiary institute in Italy.
Surace A; Baù MG; Privitera S; Botta G; Danese S; Plazzotta C; Mitidieri M; Picardo E
Int J Gynaecol Obstet; 2022 Feb; 156(2):236-239. PubMed ID: 33834486
[TBL] [Abstract][Full Text] [Related]
38. Morcellation and the Incidence of Occult Uterine Malignancy: A Dual-Institution Review.
Picerno TM; Wasson MN; Gonzalez Rios AR; Zuber MJ; Taylor NP; Hoffman MK; Borowsky ME
Int J Gynecol Cancer; 2016 Jan; 26(1):149-55. PubMed ID: 26332395
[TBL] [Abstract][Full Text] [Related]
39. Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy.
Wright JD; Tergas AI; Cui R; Burke WM; Hou JY; Ananth CV; Chen L; Richards C; Neugut AI; Hershman DL
JAMA Oncol; 2015 Apr; 1(1):69-77. PubMed ID: 26182307
[TBL] [Abstract][Full Text] [Related]
40. Reply: To PMID 25460521.
Lieng M; Berner E; Busund B
J Minim Invasive Gynecol; 2015; 22(4):697. PubMed ID: 25623372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
